| Index | — | P/E | — | EPS (ttm) | -10.69 | Insider Own | 0.79% | Shs Outstand | 109.75M | Perf Week | 3.33% |
| Market Cap | 5.41B | Forward P/E | 7.96 | EPS next Y | 6.19 | Insider Trans | 0.58% | Shs Float | 99.80M | Perf Month | 11.54% |
| Enterprise Value | 16.37B | PEG | — | EPS next Q | 1.56 | Short Float | 5.79% | Perf Quarter | 12.33% | ||
| Income | -1.17B | P/S | 0.56 | EPS this Y | 41.55% | Short Ratio | 3.20 | Perf Half Y | -28.80% | ||
| Sales | 9.71B | P/B | 1.18 | EPS next Y | 2.82% | ROA | -5.46% | Short Interest | 5.78M | Perf YTD | 16.60% |
| Book/sh | 41.80 | P/C | 3.97 | EPS next 5Y | 25.67% | ROE | -28.81% | 52W High | 70.70 -30.27% | Perf Year | 22.88% |
| Cash/sh | 12.43 | P/FCF | 7.64 | EPS past 3/5Y | — | ROIC | -3.79% | 52W Low | 35.13 40.34% | Perf 3Y | -56.35% |
| Dividend Est. | 0.12 (0.24%) | EV/EBITDA | 42.52 | Sales past 3/5Y | -0.45% 11.03% | Gross Margin | 20.23% | Volatility | 3.29% 3.54% | Perf 5Y | -70.74% |
| Dividend TTM | 0.12 (0.24%) | EV/Sales | 1.69 | EPS Y/Y TTM | — | Oper. Margin | -7.02% | ATR (14) | 1.67 | Perf 10Y | -30.47% |
| Dividend Ex-Date | Oct 27, 2026 | Quick Ratio | 0.74 | Sales Y/Y TTM | -2.28% | Profit Margin | -12.04% | RSI (14) | 64.78 | Recom | 2.81 |
| Dividend Gr. 3/5Y | -64.75% -45.43% | Current Ratio | 1.23 | EPS Q/Q | 70.14% | SMA20 | 5.58% | Beta | 0.70 | Target Price | 53.63 |
| Payout | — | Debt/Eq | 2.69 | Sales Q/Q | 8.69% | SMA50 | 7.10% | Rel Volume | 0.88 | Prev Close | 48.32 |
| Employees | 11,434 | LT Debt/Eq | 2.40 | Earnings | Nov 02 | SMA200 | -4.46% | Avg Volume | 1.71M | Price | 49.30 |
| IPO Date | Jan 21, 2005 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.88% 0.24% | Net Debt/EBITDA | 28.47 | Volume | 1,500,288 | Change | 2.03% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Reiterated | RBC Capital | Sector Perform | $68 → $46 |
| Oct-12-26 | Initiated | Barclays | Equal Weight | $151 → $49 |
| Sep-10-26 | Initiated | KeyBanc | Overweight | $70 → $57 |
| Aug-06-26 | Reiterated | Deutsche Bank | Buy | $60 → $50 |
| Aug-06-26 | Reiterated | Wells Fargo | Overweight | $75 → $65 |
| Aug-05-26 | Reiterated | Mizuho Securities | Neutral | $55 → $50 |
| Aug-05-26 | Reiterated | BMO Capital | Market Perform | $57 → $54 |
| Jul-22-26 | Reiterated | Deutsche Bank | Buy | $52 → $60 |
| Jul-16-26 | Reiterated | Morgan Stanley | Equal Weight | $50 → $58 |
| Jul-06-26 | Reiterated | BMO Capital | Market Perform | $47 → $57 |
Celanese Corporation produces and sells engineered polymers worldwide. It operates through Engineered Materials and Acetyl Chain segments. The company offers ethylene acrylic elastomers, ethylene vinyl acetate pharmaceutical grade copolymers, liquid crystal polymers, long-fiber reinforced thermoplastics, nylon and polypropylene compounds and formulations, polyoxymethylene, ultra-high molecular weight polyethylene, and thermoplastic elastomers, polyesters, and vulcanizates for use in appliance, automotive, construction, consumer apparel, consumer electronics, electrical, energy storage, filtration equipment, industrial, medical, and telecommunication applications. It also provides acetic acid and anhydride, acetate flakes and tows, butyl acetates, emulsion polymers, ethyl acetates, ethylene vinyl acetate resins and compounds, formaldehydes, redispersible powders, and vinyl acetate monomers for use in adhesives, automotive parts, coatings, consumer goods, external thermal insulation composite systems, films, filtration, flexible packaging, food and beverage, food packaging, inks, lamination, lubricants, paints, paper finishing, pharmaceuticals, plasticizers, plasters and renders, solvents, textiles, and tiling applications. The company offers its products under the Amcel, AOPlus, Ateva, Avicor, Celanese, Celanex, Celanyl, Celcon, Celstran, Celvolit, Clarifoil, Crastin, Dur-O-Set, Dytron, ECOMID, EcoVAE, Elotex, Factor, Flexbond, Forprene, FRIANYL, Fortron, Geolast, GHR, GUR, Hostaform, Hytrel, Laprene, Melinex, MetaLX, Mowilith, MT, Mylar, NILAMID, Nylfor, OmniLon, Pibifor, Pibiter, Polifor, Resyn, Rynite, Santoprene, SlideX, Sofprene, Sofpur, Talcoprene, Tarnoform, Tecnoprene, TufCOR, Tynex, Vamac, VAntage, Vectra, Vinac, Vinamul, VitalDose, Zenite, and Zytel brands. It sells its products directly to customers and through distributors; and original equipment manufacturers and suppliers. Celanese Corporation was founded in 1912 and is headquartered in Irving, Texas.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 9,712 | 9,544 | 10,280 | 10,940 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 7,747 | 7,753 | 7,924 | 8,337 | — | — | — | — | — | |
| Gross Profit | 1,965 | 1,791 | 2,356 | 2,603 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 931 | 899 | 1,030 | 1,075 | — | — | — | — | — | |
| Research and Development | 120 | 125 | 130 | 146 | — | — | — | — | — | |
| Other Operating Expense | 1,596 | 0 | 1,893 | -305 | — | — | — | — | — | |
| Operating Income | -682 | 767 | -697 | 1,687 | — | — | — | — | — | |
| Interest Expense | 760 | 769 | 676 | 720 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 319 | -1,218 | 377 | 216 | — | — | — | — | — | |
| Net Income Before Taxes | -1,123 | -1,220 | -996 | 1,183 | — | — | — | — | — | |
| Income Taxes | 22 | -90 | 510 | -790 | — | — | — | — | — | |
| Consolidated Net Income | -1,169 | -1,165 | -1,522 | 1,960 | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,145 | -1,130 | -1,506 | 1,973 | — | — | — | — | — | |
| Net Income | -1,169 | -1,165 | -1,522 | 1,960 | — | — | — | — | — | |
| EPS (Recurring) | -10.68 | -10.64 | -13.93 | 18.01 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -10.68 | -10.64 | -13.93 | 18.01 | — | — | — | — | — | |
| EPS (Diluted) | -10.69 | -10.64 | -13.93 | 17.92 | — | — | — | — | — | |
| EBITDA | 385 | 335 | 503 | 2,614 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | 8.67 | — | — | — | — | — | |
| Price To Sales Ratio | 0.56 | 0.49 | 0.73 | 1.55 | — | — | — | — | — | |
| Gross Margin | 20.23 | 18.77 | 22.92 | 23.79 | — | — | — | — | — | |
| Operating Margin | -7.02 | 8.04 | -6.78 | 15.42 | — | — | — | — | — | |
| Net Margin | -12.04 | -12.21 | -14.81 | 17.92 | — | — | — | — | — | |
| Shares Outstanding | 110 | 110 | 109 | 109 | — | — | — | — | — | |
| Market Capitalization | 5,423 | 4,651 | 7,544 | 16,935 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kyrish Chuck | SVP & CFO | Aug 14 '26 | Buy | 45.52 | 2,300 | 104,699 | 29,114 | Aug 17 |
| Duffie Ashley B | SVP & GC | Aug 11 '26 | Buy | 45.60 | 600 | 27,360 | 31,925 | Aug 13 |
| Murray Mark Christopher | SVP - Acetyls | Aug 11 '26 | Buy | 45.52 | 2,153 | 98,004 | 30,432 | Aug 12 |
| Richardson Scott A | CEO & President | Dec 10 '25 | Buy | 41.59 | 3,800 | 158,042 | 70,449 | Dec 12 |
| Kyrish Chuck | SVP & CFO | Dec 09 '25 | Buy | 41.03 | 5,000 | 205,150 | 10,914 | Dec 11 |
| Go Timothy | Director | Sep 08 '25 | Buy | 46.25 | 1,039 | 48,053 | 4,415 | Sep 09 |
| Murray Mark Christopher | SVP - Acetyls | Aug 14 '25 | Buy | 41.83 | 2,017 | 84,371 | 17,000 | Aug 18 |
| Sutton Scott McDougald | Director | Aug 14 '25 | Buy | 40.89 | 2,000 | 81,787 | 20,376 | Aug 18 |
| MOORTHY GANESH | Director | Aug 14 '25 | Buy | 40.94 | 1,000 | 40,942 | 6,015 | Aug 18 |
| GALANTE EDWARD G | Director | Aug 14 '25 | Buy | 41.27 | 2,400 | 99,053 | 21,377 | Aug 18 |
| Murray Mark Christopher | SVP - Acetyls | May 23 '25 | Buy | 52.18 | 1,479 | 77,174 | 15,468 | May 28 |
| MOORTHY GANESH | Director | Mar 12 '25 | Buy | 53.29 | 1,000 | 53,290 | 3,000 | Mar 13 |
| MOORTHY GANESH | Director | Mar 07 '25 | Buy | 54.67 | 1,000 | 54,670 | 2,000 | Mar 10 |
| Sutton Scott McDougald | Director | Mar 07 '25 | Buy | 54.65 | 7,450 | 407,119 | 15,000 | Mar 10 |
| Murray Mark Christopher | SVP - Acetyls | Mar 07 '25 | Buy | 54.45 | 2,353 | 128,110 | 13,989 | Mar 10 |